Prime Medicine
187 employees
Biotech/Pharma
Public · $490.0M
Total raised
$490.0M
Last stage
Public
Investors
David R. Liu
Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad Institute of MIT and Harvard. Pioneer of Prime Editing and Base Editing technologies. Co-founder of multiple biotech companies including Beam Therapeutics and Editas Medicine.
Keith Gottesdiener
MD. Biotech veteran who led Prime Medicine as President and CEO from founding. Previously helmed Rhythm Pharmaceuticals.
LinkedIn
Andrew Anzalone
MD, PhD. Co-developed Prime Editing technology at the Broad Institute of MIT and Harvard. Joined Prime Medicine as Chief Scientific Officer.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.